Following is a transcript of their remarks:
Susan O'Brien, MD: Hi, everyone, and welcome to this roundtable where we're going to discuss CLL presentations at ASH 2020 this year. I'm Dr. Susan O'Brien from the Chao Family Comprehensive Cancer Center at the University of California in Irvine, and I'm joined by two esteemed colleagues, Dr. Jennifer Brown from Dana-Farber and Dr. Anthony Mato from Memorial Sloan Kettering.
We have two presentations today on the TRANSCEND clinical trial, and that is an interesting CAR-T trial of liso-cel which targets CD19, like many of the other CAR-Ts, but is a little bit different in that it has a defined component of CD4 and CD8 cells, which I think is the only CAR-T that's actually doing that. One of the presentations involved just the CAR-T alone and the other was the CAR-T given in combination with ibrutinib. Jennifer, maybe you could speak to that and the rationale for actually giving it with ibrutinib in the sense that many of the patients had failed ibrutinib?